Pharming Group (PHGUF) to Announce Earnings on Thursday

Pharming Group (OTCMKTS:PHGUF) is expected to be posting its resultson Thursday, July 30th. Analysts expect Pharming Group to announce earnings of $0.0063 per share and revenue of $99.5160 million for the quarter.

Pharming Group (OTCMKTS:PHGUF) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.01) earnings per share for the quarter. Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The company had revenue of $72.45 million during the quarter, compared to analyst estimates of $92.06 million.

Pharming Group Stock Performance

Shares of OTCMKTS PHGUF opened at $1.30 on Tuesday. The stock has a market capitalization of $872.39 million, a PE ratio of 65.03 and a beta of 0.47. The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.40. The stock has a fifty day simple moving average of $1.24 and a 200-day simple moving average of $1.52. Pharming Group has a twelve month low of $1.14 and a twelve month high of $2.17.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.